{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:30Z","timestamp":1791868950045,"version":"4.3.4"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>\n                    IgA nephropathy (IgAN) is a common chronic glomerular disease that, in most patients, slowly progresses to ESRD. The immune and autoimmune responses that characterize IgAN indicate a potential benefit for corticosteroids. The 2012 Kidney Disease Improving Global Outcome (KDIGO) guidelines suggest giving corticosteroids to patients with rather preserved renal function (GFR&gt;50 ml\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    ) and persistent proteinuria &gt;1 g\/d, despite 3\u20136 months of optimized supportive care with renin-angiotensin system blockers. However, the evidence supporting this guideline was considered of low quality. More recent results from large cohort studies and randomized, controlled trials have provided conflicting messages about the benefits of corticosteroid treatment over supportive care alone, mostly involving optimized renin-angiotensin system blockade, which might generate further uncertainty in the therapeutic choice. Overall, these results indicate that corticosteroids are a powerful tool for treating patients with IgAN; however, treatment success is not universal and mostly occurs in patients who are highly proteinuric with early CKD. In patients with advanced CKD, the side effects of corticosteroids increase, and the renal protection decreases. This brief review aimed at integrating the findings of these recently published reports to provide balanced advice for clinicians as well as suggestions for future trials.\n                  <\/jats:p>","DOI":"10.1681\/asn.2016060647","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T22:59:55Z","timestamp":1474930795000},"page":"25-33","source":"Crossref","is-referenced-by-count":52,"title":["Corticosteroids in IgA Nephropathy: Lessons from Recent Studies"],"prefix":"10.1681","volume":"28","author":[{"given":"Rosanna","family":"Coppo","sequence":"first","affiliation":[{"name":"Fondazione Ricerca Molinette, Nephrology, Dialysis and Transplantation, Regina Margherita Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"B1-20230819","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy.","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"B2-20230819","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneph.2014.92","article-title":"Pathology of IgA nephropathy.","volume":"10","author":"Roberts","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"B3-20230819","first-page":"503","article-title":"Factors predicting progression of IgA nephropathies.","volume":"18","author":"Coppo","year":"2005","journal-title":"J Nephrol"},{"key":"B4-20230819","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1681\/ASN.2010040355","article-title":"Predicting the risk for dialysis or death in IgA nephropathy.","volume":"22","author":"Berthoux","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230819","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00467-012-2294-6","article-title":"Spontaneous remission in children with IgA nephropathy.","volume":"28","author":"Shima","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B6-20230819","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1681\/ASN.2012010063","article-title":"Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria.","volume":"23","author":"Guti\u00e9rrez","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B8-20230819","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000065281","article-title":"Idiopathic IgA nephropathy with diffuse crescent formation.","volume":"22","author":"Tang","year":"2002","journal-title":"Am J Nephrol"},{"key":"B9-20230819","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy.","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230819","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int"},{"key":"B11-20230819","first-page":"1668","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.","volume":"119","author":"Suzuki","year":"2009","journal-title":"J Clin Invest"},{"key":"B12-20230819","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-pathol-011110-130216","article-title":"IgA nephropathy: Molecular mechanisms of the disease.","volume":"8","author":"Mestecky","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"B13-20230819","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.","volume":"88","author":"Magistroni","year":"2015","journal-title":"Kidney Int"},{"key":"B14-20230819","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/17530059.2013.856878","article-title":"Biomarkers in IgA nephropathy: Relationship to pathogenetic hits.","volume":"7","author":"Hastings","year":"2013","journal-title":"Expert Opin Med Diagn"},{"key":"B15-20230819","article-title":"Biomarkers and targeted new therapies for IgA nephropathy [published online ahead of print June 20, 2016].","author":"Coppo","journal-title":"Pediatr Nephrol"},{"key":"B16-20230819","first-page":"935","article-title":"Steroid therapy in IgA nephropathy: A prospective pilot study in moderate proteinuric cases.","volume":"61","author":"Kobayashi","year":"1986","journal-title":"Q J Med"},{"key":"B17-20230819","first-page":"1135","article-title":"Effect of corticosteroids on renal function in progressive IgA nephropathy--long-term follow-up study.","volume":"30","author":"Kobayashi","year":"1988","journal-title":"Nippon Jinzo Gakkai Shi"},{"key":"B18-20230819","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000414332","article-title":"The secretory immune system.","volume":"39","author":"Vaerman","year":"1987","journal-title":"Antibiot Chemother (1971)"},{"key":"B19-20230819","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/eji.1830191210","article-title":"Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: Inhibition of IgG-mediated complement activation.","volume":"19","author":"Russell","year":"1989","journal-title":"Eur J Immunol"},{"key":"B20-20230819","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1155\/S0962935196000269","article-title":"Dimeric and polymeric IgA, but not monomeric IgA, enhance the production of IL-6 by human renal mesangial cells.","volume":"5","author":"Reterink","year":"1996","journal-title":"Mediators Inflamm"},{"key":"B21-20230819","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/j.1523-1755.2004.05407.x","article-title":"Aberrant glycosylation in IgA nephropathy (IgAN).","volume":"65","author":"Coppo","year":"2004","journal-title":"Kidney Int"},{"key":"B22-20230819","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ndt\/gfm581","article-title":"Synthesis of TNF-alpha by mesangial cells cultured with polymeric anionic IgA--role of MAPK and NF-kappaB.","volume":"23","author":"Leung","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20230819","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/1566524054553450","article-title":"Molecular basis of IgA nephropathy.","volume":"5","author":"Lai","year":"2005","journal-title":"Curr Mol Med"},{"key":"B24-20230819","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.rinim.2012.08.002","article-title":"In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells.","volume":"2","author":"Yanagihara","year":"2012","journal-title":"Results Immunol"},{"key":"B25-20230819","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nri3322","article-title":"New concepts in the generation and functions of IgA.","volume":"12","author":"Pabst","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B26-20230819","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: A randomised controlled trial.","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"B27-20230819","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B28-20230819","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial.","volume":"53","author":"Lv","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"B29-20230819","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis.","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"B30-20230819","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1523-1755.2004.00874.x","article-title":"Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1.","volume":"66","author":"Lai","year":"2004","journal-title":"Kidney Int"},{"key":"B31-20230819","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial.","volume":"14","author":"Praga","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B32-20230819","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B33-20230819","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study.","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"B34-20230819","first-page":"139","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis. Immunoglobulin A nephropathy.","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B35-20230819","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial.","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B36-20230819","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B37-20230819","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: Clinical and histological response to methylprednisolone and intravenous cyclophosphamide.","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B38-20230819","first-page":"CD003965","article-title":"Immunosuppressive agents for treating IgA nephropathy.","volume":"3","author":"Vecchio","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B39-20230819","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.","volume":"21","author":"Pozzi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B40-20230819","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrneph.2010.31","article-title":"Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy?","volume":"6","author":"Eitner","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B41-20230819","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility.","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"B42-20230819","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification.","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"B43-20230819","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ki.2011.126","article-title":"Validation of the Oxford classification of IgA nephropathy.","volume":"80","author":"Herzenberg","year":"2011","journal-title":"Kidney Int"},{"key":"B44-20230819","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000332223","article-title":"The Oxford classification of IgA nephropathy: A retrospective analysis.","volume":"34","author":"Yau","year":"2011","journal-title":"Am J Nephrol"},{"key":"B45-20230819","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.2215\/CJN.01170211","article-title":"The use of the Oxford classification of IgA nephropathy to predict renal survival.","volume":"6","author":"Alamartine","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B46-20230819","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.ajkd.2012.06.011","article-title":"A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients.","volume":"60","author":"Zeng","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B47-20230819","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.2215\/CJN.02890311","article-title":"Validation study of oxford classification of IgA nephropathy: The significance of extracapillary proliferation.","volume":"6","author":"Katafuchi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B48-20230819","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2215\/CJN.11521210","article-title":"Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: Validation of the Oxford classification.","volume":"6","author":"Shi","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B49-20230819","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1053\/j.ajkd.2013.04.021","article-title":"Evaluation of the Oxford Classification of IgA nephropathy: A systematic review and meta-analysis.","volume":"62","author":"Lv","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B50-20230819","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"B51-20230819","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA Study.","volume":"26","author":"Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B52-20230819","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy.","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"B53-20230819","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD.","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B54-20230819","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy.","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B55-20230819","doi-asserted-by":"crossref","first-page":"e101935","DOI":"10.1371\/journal.pone.0101935","article-title":"Optimal proteinuria target for renoprotection in patients with IgA nephropathy.","volume":"9","author":"Nam","year":"2014","journal-title":"PLoS One"},{"key":"B57-20230819","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy.","volume":"11","author":"Sarcina","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B58-20230819","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMc1600141","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy.","volume":"374","author":"Ayoub","year":"2016","journal-title":"N Engl J Med"},{"key":"B59-20230819","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1681\/ASN.2011111112","article-title":"Corticosteroid therapy in IgA nephropathy.","volume":"23","author":"Lv","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B60-20230819","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5301\/jn.5000110","article-title":"IgA nephropathy with severe chronic renal failure: A randomized controlled trial of corticosteroids and azathioprine.","volume":"26","author":"Pozzi","year":"2013","journal-title":"J Nephrol"},{"key":"B61-20230819","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in IgA nephropathy.","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"B62-20230819","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/ajkd.2001.27689","article-title":"Predicting progression in IgA nephropathy.","volume":"38","author":"Bartosik","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B63-20230819","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/ndt\/gfu343","article-title":"The intestine-renal connection in IgA nephropathy.","volume":"30","author":"Coppo","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B64-20230819","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: Enteric budesonide targeted to the ileocecal region ameliorates proteinuria.","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B65-20230819","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ki.2015.94","article-title":"Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction.","volume":"88","author":"Papista","year":"2015","journal-title":"Kidney Int"},{"key":"B66-20230819","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy.","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"B67-20230819","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"B68-20230819","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ndt\/gfn441","article-title":"Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy.","volume":"24","author":"Lai","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B69-20230819","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/ki.2009.473","article-title":"Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes.","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"B70-20230819","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/bcp.12104","article-title":"Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease.","volume":"76","author":"Cravedi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B71-20230819","first-page":"385","article-title":"Proteinuria: Clinical significance and basis for therapy.","volume":"42","author":"Woo","year":"2001","journal-title":"Singapore Med J"},{"key":"B72-20230819","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/ndt\/gft016","article-title":"Is a legacy effect possible in IgA nephropathy?","volume":"28","author":"Coppo","year":"2013","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201701000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:28:20Z","timestamp":1786130900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201701000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2016060647","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]}}}